BOTOX® Cosmetic and BOTOX® (Botulinum Toxin Type A) By the Numbers

• 3,181,592: Number of BOTOX® Cosmetic treatments administered in the United States in 2006
alone

• 1,000,000s: People who received treatment with BOTOX® for medical and aesthetic purposes
around the world

• 300,000: Number of men who received treatment with BOTOX® Cosmetic in 2006

• 10,000: People in clinical trials

• 3,000: Publications on Botulinum Toxin Type A in scientific and medical journals

• 100: Years of study into botulinum neurotoxins

• 97: Percentage of people satisfied with their BOTOX® Cosmetic treatment based on a survey of
   approximately 1,000 patients

• 75: Countries around the world who have approved use of BOTOX®

• 20: BOTOX® indications approved by regulatory authorities around the world, including the aesthetic 
   indication

• 18: Years since U.S. Food and Drug Administration (FDA) approved BOTOX® to treat excessive eye 
   blinking and crossed eyes

• 11: Descriptor for the glabellar (vertical) lines between the brows which can be treated with BOTOX®
   Cosmetic, that can help improve one’s overall facial appearance

• 8: Years since FDA approval of BOTOX® for the treatment of cervical dystonia (painful neck twisting
   condition) in adults

• 6: Years since FDA approval of BOTOX® Cosmetic for the treatment of the moderate to severe
   glabellar (vertical) lines between the brows in adults 18 to 65

• 4: Years since FDA approval of BOTOX® for the treatment of severe primary hyperhidrosis (excessive
   underarm sweating) inadequately managed with topical agents

• 1: Rank of BOTOX® Cosmetic on list of “Top 5 Surgical & Nonsurgical Physician Administered
   Cosmetic Procedures,” according to American Society for Aesthetic Plastic Surgery

About BOTOX® (Botulinum Toxin Type A)

BOTOX® is a medical product that contains tiny amounts of highly purified botulinum toxin protein refined from a bacterium. The product is administered in small therapeutic doses by injection directly into the affected area, and works by blocking the release of acetylcholine (a neurotransmitter that signals the
muscles to contract) at the neuromuscular junction.

BOTOX® neurotoxin therapy was granted approval by the FDA in 1989 for the treatment of strabismus
(crossed eyes) and blepharospasm (uncontrollable eye blinking) associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. The efficacy of BOTOX® treatment in deviations over 50 prism diopters, in restrictive strabismus, in Duane’s syndrome with lateral rectus weakness, and in secondary strabismus caused by prior surgical over-recession of the
antagonist has not been established. BOTOX® is ineffective in chronic paralytic strabismus except when
used in conjunction with surgical repair to reduce antagonist contracture.

BOTOX® neurotoxin has since received approval in December 2000 for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.

In 2002, with dosing specific to treat frown lines between the eyebrows, the product was approved by the FDA for the temporary improvement in the appearance of moderate to severe glabellar lines (the vertical “frown lines” between the eyebrows) in adult men and women aged 65 and younger, under the name BOTOX® Cosmetic. More recently, in July 2004, BOTOX® was granted FDA approval for the treatment of
severe primary axillary hyperhidrosis (excessive underarm sweating) that is inadequately managed with
topical agents.

BOTOX® Cosmetic (Botulinum Toxin Type A) Fact Sheet

•
More than 13 million aesthetic procedures with BOTOX® Cosmetic (botulinum toxin type A) have
been administered since the product was first approved in 2002 in the United States for temporary
treatment of moderate to severe glabellar lines (the vertical “frown lines” between the eyebrows) in
adults 18 to 65.i
•
According to the American Society for Aesthetic Plastic Surgery (ASAPS), more than three million
BOTOX® Cosmetic treatments were administered in 2006 alone.ii
•
Ninety-seven percent of patients were definitely satisfied with BOTOX® Cosmetic treatments,
according to a survey of approximately 1,000 patients conducted by the research arm of ASAPS.iii
•
BOTOX® Cosmetic, approved for the temporary treatment of glabellar lines, is the same medicine
that is used to treat patients with neurological conditions under the name BOTOX®. It is, however,
administered in much smaller doses for aesthetic use. The approved doses of BOTOX® for medical
uses are significantly greater than the approved dose for an aesthetic procedure.
•
BOTOX® Cosmetic is a simple, minimally invasive injectable treatment that creates a temporary
smoothed and improved appearance of the wrinkle-causing muscles between the brows that lasts up
to four months. Most side effects are temporary and typically associated with the injection itself, such
as localized pain, tenderness, redness and/or bruising. (See full safety information provided below).
•
Since its first approval more than 18 years ago, reports of serious adverse events in patients
receiving BOTOX® have been rare.
•
BOTOX® Cosmetic should only be administered by a licensed health care professional (HCP) who is
well trained in the anatomy of the face.